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Background The age at which heart failure develops varies widely between countries and drug tolerance and outcomes also vary by
age. We have examined the efficacy and safety of LCZ696 according to age in the Prospective comparison of angioten-
sin receptor neprilysin inhibitor with angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality
and Morbidity in Heart Failure trial (PARADIGM-HF).
Methods In PARADIGM-HF, 8399 patients aged 18–96 years and in New York Heart Association functional class II– IV with an
LVEF ≤40% were randomized to either enalapril or LCZ696. We examined the pre-specified efficacy and safety out-
comes according to age category (years):,55 (n ¼ 1624), 55–64 (n ¼ 2655), 65–74 (n ¼ 2557), and ≥75 (n ¼ 1563).
Findings The rate (per 100 patient-years) of the primary outcome of cardiovascular (CV) death or heart failure hospitalization
(HFH) increased from 13.4 to 14.8 across the age categories. The LCZ696:enalapril hazard ratio (HR) was ,1.0 in all
categories (P for interaction between age category and treatment ¼ 0.94) with an overall HR of 0.80 (0.73, 0.87),
P, 0.001. The findings for HFH were similar for CV and all-cause mortality and the age category by treatment inter-
actions were not significant. The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia
increased in both treatment groups with age, although the differences between treatment (more hypotension but less
renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.
Interpretation LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit–
risk profile in all age groups.
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Introduction
The age at which heart failure develops varies widely between coun-
tries.1 – 4 Although characteristically considered a condition of the
elderly in Western Europe and North America, patients with heart
failure in other regions of the world such as Asia and Latin America
are often much younger.1– 4 This is one reason why the average age
of patients with heart failure in large international trials is typically a
decade or more younger than in clinical practice in the northern
hemisphere. Trial exclusion criteria based on comorbidity and other
factors may also lead to fewer elderly than younger patients being
enrolled in trials.1 –4
Understandably, however, physicians who treat older individuals
want to know about the efficacy and tolerability of new treatments
in their patients. For this reason, we have conducted an analysis of out-
comes in the Prospective comparison of angiotensin receptor nepri-
lysin inhibitor (ARNI) with angiotensin converting enzyme inhibitor to
Determine Impact on Global Mortality and morbidity in Heart Failure
trial (PARADIGM-HF) according to age PARADIGM-HF randomized
8399 patients aged 18–96 years in 47 countries to treatment with en-
alapril 10 mg twice daily or the ARNI LCZ696 (sacubitril-valsartan)
200 mg twice daily.5–7
Methods
The design and primary results of the PARADIGM-HF trial have been
previously described.5–7 The Ethics Committee of each of the 1043 par-
ticipating institutions (in 47 countries) approved the protocol, and all
patients gave written, informed consent.
Study patients
Patients had New York Heart Association (NYHA) class II– IV symp-
toms, an ejection fraction ≤40% (changed to ≤35% by amendment),
and a plasma B-type natriuretic peptide (BNP) ≥150 pg/mL
[or N-terminal pro-BNP (NTproBNP) ≥600 pg/mL]. Patients who
had been hospitalized for heart failure within 12 months were eligible
with a lower natriuretic peptide concentration (BNP ≥100 pg/mL or
NTproBNP ≥400 pg/mL). Patients were required to be taking an
ACE inhibitor or ARB in a dose equivalent to enalapril 10 mg daily for
at least 4 weeks before screening, along with a stable dose of ab-blocker
(unless contraindicated or not tolerated) and a mineralocorticoid antag-
onist (if indicated). The exclusion criteria included history of intolerance
of ACE inhibitors or angiotensin receptor blockers, symptomatic hypo-
tension (or a systolic blood pressure ,100 mmHg at screening/,95
mmHg at randomization), an estimated glomerular filtration rate
(GFR) ,30 mL/min/1.73 m2, a serum potassium concentration
.5.2 mmol/L at screening (.5.4 mmol/L at randomization) and a his-
tory of angioedema.
Study procedures
On trial entry, existing treatment with an ACE inhibitor or angiotensin
receptor blocker was stopped, but other treatments for heart failure
were continued. Patients first received enalapril 10 mg twice daily for
2 weeks (single-blind) and then LCZ696 (single-blind) for an additional
4–6 weeks, initially at 100 mg twice daily and then 200 mg twice daily.
Patients tolerating both drugs at target doses were randomly assigned in
a 1:1 ratio to double-blind treatment with either enalapril 10 mg twice
daily or LCZ696 200 mg twice daily. LCZ696 200 mg twice daily deli-
vers the equivalent of valsartan 160 mg twice daily and significant and
sustained neprilysin inhibition.
Study outcomes
The primary outcome was a composite of death from cardiovascular
(CV) causes or a first hospitalization for heart failure. The secondary
outcomes were the time to death from any cause, the change from base-
line to 8 months in the clinical summary score on the Kansas City Car-
diomyopathy Questionnaire (KCCQ) (on a scale from 0 to 100, with
higher scores indicating fewer symptoms and physical limitations asso-
ciated with heart failure),8 the time to a new onset of atrial fibrillation,
and the time to the first occurrence of a decline in renal function (which
was defined as end-stage renal disease or a decrease in eGFR of ≥50%
or a decrease of .30 mL per minute per 1.73 m2 from randomization
to ,60 mL per minute per 1.73 m2); there were too few patients with
new onset atrial fibrillation and decline in renal function for meaningful
analysis by age category. Safety outcomes included hypotension, eleva-
tion of serum creatinine, hyperkalaemia, cough and angioedema, as pre-
viously reported.6
Statistical analysis
The trial was designed to recruit 8000 patients and continue until
2410 patients experienced either a first hospitalization for heart failure
or CV death (primary outcome) during which time it was expected that
1229 patients would experience CV death. However, an independent
Data and Safety Monitoring Board recommended early termination
of the study (50 months after the first patient was randomized)
when the boundary for overwhelming benefit for both CV mortality
and the primary outcome had been crossed.
In the present study, patients were divided into four arbitrary age cat-
egories: (i) ,55 years, (ii) 55–64 years, (iii) 65–74 years, and (iv) ≥75
years. The primary composite outcome, its components and all-cause
mortality were analysed for each category, as was study-drug toleration
and safety. The effect of LCZ696 compared with enalapril on each out-
come across the spectrum of age was examined in a Cox regression
model. Age was modelled as a continuous variable. A fractional polyno-
mial was constructed of age and entered into the model as an inter-
action term with treatment.9 The results of the interaction were
displayed graphically using the mfpi command in STATA.10 The inter-
action between age and treatment on the occurrence of the pre-
specified safety outcomes was tested in a logistic regression model
with an interaction term between age and treatment. We also examined
a sex by treatment interaction and an age by treatment by sex inter-
action. The proportion with a 5 point fall on the KCCQ questionnaire
at 8 months was examined in a logistic regression model with an inter-
action term between age and treatment. The effect of region and differ-
ences in baseline characteristics was examined by adjustment of the
model in sensitivity analysis as well as a region by age by treatment inter-
action. All analyses were conducted using STATA version 12.1 (College
Station, TX, USA) and SAS version 9.4 (SAS Institute Inc., Cary, NC,
USA). A P-value of ,0.05 was considered statistically significant.
Results
Overall, 8399 patients aged 18–96 years were validly randomized.
The mean (median) age was 63.8 (64) years. Table 1 shows the num-
ber and proportion of patients in the different age categories ana-
lysed. There were 1563 (18.6%) patients aged ≥75 years, 587
(7.0%) aged ≥80 years, and 121 (1.44%) aged ≥85 years.
Patient characteristics
Compared with younger patients, those that were older were more
often female, white and enrolled in Western Europe and North
America. Older patients also had higher systolic blood pressure,
Effect of LCZ696 by age in heart failure 2577
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Table 1 Baseline characteristics and treatment according to age category
<55 years
(n5 1624)
55–64 years
(n 5 2655)
65–74 years
(n 5 2557)
≥75 years
(n 5 1563)
P for
trend
Age (years) 46.7+6.7 59.94+2.9 69.3+2.9 79.1+3.5
Female, N (%) 321 (19.8%) 500 (18.8%) 584 (22.8%) 427 (27.3%) ,0.001
Race, N (%) ,0.001
White 703 (43.3%) 1714 (64.6%) 1879 (73.5%) 1248 (79.8%)
Black 168 (10.3%) 141 (5.3%) 87 (3.4%) 32 (2.0%)
Asian 544 (33.5%) 507 (19.1%) 339 (13.3%) 119 (7.6%)
Other 209 (12.9%) 293 (11.0%) 252 (9.9%) 164 (10.5%)
Region, N (%) ,0.001
North America 102 (6.3%) 180 (6.8%) 197 (7.7%) 123 (7.9%)
Latin America 315 (19.4%) 453 (17.1%) 421 (16.5%) 244 (15.6%)
Western Europe and Other 261 (16.1%) 561 (21.1%) 678 (26.5%) 551 (35.3%)
Central Europe 411 (25.3%) 959 (36.1%) 928 (36.3%) 528 (33.8%)
Asia-Pacific 535 (32.9%) 502 (18.9%) 333 (13.0%) 11 (7.5%)
SBP (mmHg) 117+ 15 121+15 122+15 125+16 ,0.001
DBP (mmHg) 75+ 11 74+10 73+10 72+ 10 ,0.001
HR (bpm) 75+ 12 73+12 71+12 71+ 11 ,0.001
BMI (kg/m2) 29+ 6.5 28.52+5.68 28+5 27+ 4 ,0.001
Creatinine (mg/dL) 1.03+0.3 1.10+ 0.28 1.15+0.30 1.22+0.32 ,0.001
Creatinine (mmol/L) 91.4+24.3 96.9+ 24.8 101.9+ 26.1 107.4+28.2 ,0.001
Estimated GFR (mL/min/1.73 m2) 80.2+23.2 70.2+ 18.4 63.4+17.1 57.5+16.0 ,0.001
Median BNP (IQR) (pg/mL) 246 [138, 530] 252 [152, 474] 246 [155, 444] 266 [168, 467] 0.023
Median NTproBNP (IQR) (pg/mL) 1410 [795, 2925] 1491 [836, 3007] 1646 [926, 3183] 2000 [1133, 3958] ,0.001
Ischaemic aetiology N (%) 683 (42.1%) 1587 (59.8%) 1673 (65.4%) 1093 (69.9%) ,0.001
Ejection fraction (%) 27.70+6.34 29.29+6.14 29.95+ 6.18 30.92+5.83 ,0.001
NYHA Class N (%) ,0.001
I 111 (6.8%) 129 (4.9%) 98 (3.8%) 51 (3.3%)
II 1212 (74.8%) 1901 (71.6%) 1798 (70.5%) 1008 (64.7%)
III 290 (17.9%) 603 (22.7%) 637 (25.0%) 488 (31.3%)
IV 8 (0.5%) 21 (0.8%) 19 (0.7%) 12 (0.8%)
KCCQ CSS median (IQR) 82 [66,94] 81 [65,93] 81 [64,92] 75 [58, 88] ,0.001
Medical history
Hypertension, N (%) 899 (55.4%) 1884 (71.0%) 1903 (74.4%) 1254 (80.2%) ,0.001
Diabetes, N (%) 442 (27.2%) 1008 (38.0%) 921 (36.0%) 536 (34.3%) ,0.001
Atrial fibrillation, N (%) 347 (21.4%) 868 (32.7%) 1083 (42.4%) 793 (50.7%) ,0.001
Hospitalization for heart failure, N (%) 1079 (66.4%) 1716 (64.6%) 1561 (61.1%) 918 (58.7%) ,0.001
Myocardial infarction, N (%) 468 (28.8%) 1177 (44.3%) 1238 (48.4%) 751 (48.1%) ,0.001
Stroke, N (%) 85 (5.2%) 223 (8.4%) 243 (9.5%) 174 (11.1%) ,0.001
Coronary artery bypass surgery, N (%) 137 (8.4%) 385 (14.5%) 473 (18.5%) 308 (19.7%) ,0.001
Percutaneous coronary intervention, N (%) 247 (15.2%) 629 (23.7%) 597 (23.4%) 328 (21.0%) 0.001
Treatment
ACE inhibitor, N (%) 1282 (78.9%) 2073 (78.1%) 2002 (78.3%) 1175 (75.2%) 0.023
ARB, N (%) 341 (21.0%) 588 (22.1%) 566 (22.1%) 397 (25.4%) 0.003
Diuretic, N (%) 1300 (80.1%) 2131 (80.3%) 2031 (79.4%) 1276 (81.6%) 0.47
Digoxin, N (%) 627 (38.6%) 780 (29.4%) 718 (28.1%) 414 (26.5%) ,0.001
b-Blocker, N (%) 1520 (93.6%) 2493 (93.9%) 2370 (92.7%) 1428 (91.4%) 0.003
Mineralocorticoid receptor antagonist, N (%) 1051 (64.7%) 1570 (59.1%) 1376 (53.8%) 674 (43.1%) ,0.001
Oral anticoagulant, N (%) 367 (22.6%) 832 (31.3%) 905 (35.4%) 581 (37.2%) ,0.001
Antiplatelet agent, N (%) 849 (52.3%) 1540 (58.0%) 1459 (57.1%) 888 (56.8%) 0.033
Lipid-lowering agent, N (%) 718 (44.2%) 1551 (58.4%) 1546 (60.5%) 914 (58.5%) ,0.001
Implantable cardioverter-defibrillator, N (%) 174 (10.7%) 416 (15.7%) 455 (17.8%) 198 (12.7%) 0.02
Cardiac resynchronization therapy, N (%) 68 (4.2%) 173 (6.5%) 219 (8.6%) 114 (7.3%) ,0.001
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 by guest on N
ovem
ber 9, 2015
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
creatinine, and natriuretic peptide levels, as well as a higher average
ejection fraction (Table 1 and Supplementary material online). Older
patients were more likely to be in NYHA functional class III/IV than I/II
and to have comorbidity. Median KCCQ score was similar (81–82) in
the age groups ,55, 55–64, and 65–74 years but was significantly
lower (75), i.e. worse in patients ≥75 years. With respect to back-
ground treatment for heart failure, pre-trial ACE inhibitor/ARB,
b-blocker and diuretic therapy was similar across age categories.
Use of a mineralocorticoid receptor antagonist and digoxin de-
creased with increasing age, whereas the opposite pattern was seen
for oral anticoagulant therapy.
Dose of study drug
The mean daily dose of enalapril was 19.0 mg (SD 2.8 mg), 19.0 mg
(2.7 mg), 18.9 mg (2.8 mg), and 18.5 mg (3.4 mg) in those aged,55,
55–64, 65–74, and ≥75 years , respectively (P for trend ,0.001).
In the same age groups, the mean dose of LCZ696 was 377 mg
(61 mg), 381 mg (52 mg), 371 mg (69 mg), and 367 mg (70 mg),
respectively (P for trend ,0.001).
Primary composite outcome
The unadjusted incidence of the primary composite outcome of CV
death or hospitalization for heart failure according to age is shown in
Table 2 and Figure 1A. The incidence of this endpoint in the enalapril
(control) group did not vary greatly across the age categories up to
65–74 years but was somewhat higher in those aged 75 years or
above.
The hazard ratio (HR), i.e. the effect of LCZ696 compared with en-
alapril on the primary outcome, was consistent across the spectrum
of age (Table 2 and Figure 2A), with a P-value for interaction of 0.94.
Cardiovascular death
As shown in Table 2 and Figure 1B, the rate of CV death in the
enalapril group was relatively high in the youngest age category
(,55 years). In the remainder of the patients, the rate increased
stepwise with age.
The effect of LCZ696 compared with enalapril was consistent
across the spectrum of age (Table 2 and Figure 2B). Although the
HR was over 1 at the oldest ages, the 95% CI was wide and the
P-value for interaction was not significant (P ¼ 0.92).
Heart failure hospitalization
The rate of heart failure hospitalization in the enalapril group did not
vary substantially across age categories (Table 2 and Figure 1C), ex-
cept possibly in the oldest patients.
The effect of LCZ696 compared with enalapril was consistent
across all age groups, including in the most elderly patients (Table 2
and Figure 2C) (P-value for interaction ¼ 0.81).
All-cause mortality
As shown in Table 2 and Figure 1D, the rate of death from any cause
was relatively high in the youngest patients (aged,55 years). In the re-
maining age categories, the rate of death increased with increasing age.
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Table 2 Clinical outcomes according to age category
<55 years (n5 1624) 55–64 years (n 5 2655) 65–74 years (n5 2557) ≥75 years (n 5 1563)
Outcome Enalapril
(n5 786)
LCZ696
(n 5 838)
Enalapril
(n5 1382)
LCZ696
(n5 1273)
Enalapril
(n5 1265)
LCZ696
(n 5 1292)
Enalapril
(n 5 779)
LCZ696
(n5 784)
CV death or HF hosp.
No. ratea 204
13.4
(11.7, 15.3)
178
10.4
(9.0, 12.0)
352
12.5
(11.3, 13.9)
253
9.6
(8.5, 10.8)
329
12.7
(11.4, 14.2)
275
10.1
(8.9, 11.3)
232
14.8
(13.0, 16.8)
208
12.7
(11.1, 14.6)
HRb 0.78 (0.64, 0.96) 0.76 (0.65, 0.90) 0.80 (0.68, 0.93) 0.86 (0.72, 1.04)
CV death
No. ratea 127
7.7
(6.5, 9.2)
117
6.4
(5.4, 7.7)
199
6.4
(5.6, 7.4)
144
5.1
(4.4, 6.0)
210
7.5
(6.6, 8.6)
163
5.5
(4.8, 6.5)
157
9.2
(7.9, 10.8)
134
7.7
(6.5, 9.1)
HRb 0.84 (0.65, 1.08) 0.79 (0.64, 0.98) 0.74 (0.60, 0.90) 0.84 (0.67, 1.06)
HF Hosp.
No. ratea 112
7.3
(6.1, 8.8)
93
5.4
(4.4, 6.6)
223
7.9
(7.0, 9.0)
156
5.9
(45.1, 6.9)
188
7.3
(6.3, 8.4)
169
6.2
(5.3, 7.2)
135
8.6
(7.3, 10.2)
119
7.3
(6.1, 8.7)
HRa 0.75 (0.57, 0.98) 0.74 (0.61, 0.91) 0.86 (0.70, 1.06) 0.85 (0.66, 1.09)
All-cause death
No. ratea 148
9.0
(7.6, 10.5)
131
7.2
(6.1, 8.6)
231
7.5
(6.6, 8.5)
183
6.5
(5.6, 7.5)
251
9.0
(7.9, 10.2)
215
7.3
(6.4, 8.4)
205
12.0
(10.5, 13.8)
182
10.5
(9.0, 12.1)
HRb 0.80 (0.64, 1.02) 0.87 (0.72, 1.06) 0.81 (0.68, 0.97) 0.87 (0.71, 1.07)
CV, cardiovascular; HF, heart failure; HR, hazard ratio.
aRate per 100 patient-years (95% CI). bHazard ratio (95% CI).
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The effect of LCZ696 compared with enalapril was consistent
across the spectrum of age (Table 2 and Figure 2D; P-value for inter-
action 0.99).
Effect of LCZ696 compared with enalapril
with age as a continuous variable
Figure 2 shows the effect of LCZ696 compared with enalapril graph-
ically for the four outcomes described earlier using fractional poly-
nomial analysis. These graphs show the HR for LCZ696 vs. enalapril
at each age, i.e. with age treated as a continuous variable. The poly-
nomial allows for the possibility of a non-linear effect of treatment
by age to be modelled. Consistent with the categorical analysis, risk
in the LCZ696 group was lower than in the enalapril group across
the age spectrum, except for CV mortality (and the composite of
CV mortality or heart failure hospitalization) in the most elderly, al-
though, as shown, the 95% confidence intervals were wide. The re-
lationship was also generally flat indicating that the magnitude of the
effect of LCZ696 on each outcome was similar across the spectrum
of age. This finding was also observed even after adjusting for differ-
ences in baseline characteristics. No interaction was found between
treatment and sex or between treatment, age, and sex.
Change in Kansas City Cardiomyopathy
Questionnaire score at 8 months
The proportion of patients with a fall in KCCQ score of five points
or more (i.e. a clinically meaningful deterioration) was smaller in
those treated with LCZ696 compared with patients treated with
enalapril, as shown in Figure 3. This benefit of LCZ696 over enalapril
in preventing worsening of KCCQ was consistent across the age
groups (P-value for interaction ¼ 0.90). The interaction was still
not statistically significant after adjusting for differences in baseline
characteristics (P for interaction ¼ 0.67). We also found no inter-
action between age, treatment, and region on KCCQ score (P for
interaction ¼ 0.44).
Pre-specified safety assessments
Table 3 shows the occurrence of the pre-specified adverse events of
interest according to age category. Generally, adverse effects be-
came more common with increasing age, although the absolute in-
crease in most of these was modest across the age categories. The
most common pre-specified safety outcome was symptomatic
hypotension which was reported in 7.6% of those aged ,55 years
and 11.9% of those aged ≥75 years in the enalapril group; the re-
spective proportions in the LCZ696 groups were 11.5 and 17.7%.
However, few of these patients discontinued study drug because
of hypotension. There was no interaction between age and treat-
ment on the rate of hypotension or any of the other adverse events
leading to treatment discontinuation.
Discussion
A larger number of patients with a broader range of ages were in-
cluded in PARADIGM-HF than in any previous trial in heart failure
with reduced ejection fraction. We found that patient
Figure 1 Clinical outcomes of cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, and
all-cause mortality by age category and treatment group. Rates are expressed as a rate per 100 patient-years of treatment (error bars are 95%
confidence intervals).
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Figure 2 LCZ696 to enalapril hazard ratio (line) and 95% confidence intervals (shaded area) for clinical outcomes [cardiovascular death or
heart failure hospitalization (A), cardiovascular death (B), heart failure hospitalization (C), and all-cause mortality (D)] according to age. A hazard
ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of ,1.0 favours LCZ696.
Figure 3 Proportion of patients with a five-point or greater fall (deterioration) in Kansas City Cardiomyopathy Questionnaire at 8 months by
age category and treatment.
Effect of LCZ696 by age in heart failure 2581
 by guest on N
ovem
ber 9, 2015
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
characteristics varied substantially by age, as in past trials.11– 14 Al-
though the rate of death and heart failure hospitalization increased
with age, this gradient was not as pronounced in PARADIGM-HF as
in prior trials.11– 14 The benefit of LCZ696, over enalapril, was simi-
lar across the age categories examined.
Older patients, as expected, differed from their younger counter-
parts in many ways.11– 21 As previously demonstrated, older indivi-
duals were more often women, although we did not find any
interaction between treatment and sex or treatment and sex and
age. Older patients had more comorbidities, higher average ejection
fraction but worse NYHA functional class. They were also more
likely to have an ischaemic aetiology. In addition to these differences
we found older patients to have higher natriuretic peptide concen-
trations, presumably reflecting the higher prevalence of renal dys-
function and atrial fibrillation in these individuals (and despite
their higher average ejection fraction).
The large number of countries which participated in PARADIGM-
HF also meant that interactions between age, geographic region, and
race/ethnicity were apparent. Non-white individuals and patients
from Latin America, the Asia-Pacific region, and Central/Eastern
Europe were more common in the younger age categories compared
with the older ones. These findings are consistent with the global
epidemiology of heart failure which shows heart failure often occurs
at a younger age in countries outside Western Europe and North
America where it is a condition that afflicts mainly the elderly.1
A perhaps more surprising findings of the present analyses was
the relatively shallow gradient in event rates, especially heart failure
hospitalization, across the age categories studied. The gradient was
most marked for death from any cause and steeper than for CV
mortality, i.e. our findings showed, by inference, that the greatest
age-related difference was in non-CV death. Furthermore, although
the crude event rates were somewhat higher in the ≥75 year age
group than in younger patients, the difference did not seem to be
as large as in prior trials.11 – 14 These two observations suggest
that in well-treated patients such as those in PARADIGM-HF, effect-
ive disease-modifying drugs may have attenuated the age-related
gradient in CV events that was prominent in historical studies. Des-
pite differences in baseline characteristics and crude mortality, there
was no difference in the effect of LCZ696 vs. enalapril on outcomes
across the range of age after adjusting for the baseline differences.
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Table 3 Pre-specified safety assessments
<55 years
(n 5 1624)
55–64 years
(n 5 2655)
65–74 years
(n5 2557)
≥75 years
(n5 1563)
P-value1
Enalapril LCZ696 Enalapril LCZ696 Enalapril LCZ696 Enalapril LCZ696
Hypotension
Symptomatic hypotension 60 (7.6) 96 (11.5) 111 (8.0) 158 (12.4) 124 (9.8) 195 (15.1) 93 (11.9) 139 (17.7) 0.95
Symptomatic hypotension with
SBP ,90 mmHg
12 (1.5) 24 (2.9) 12 (0.9) 33 (2.6) 21 (1.7) 32 (2.5) 14 (1.8) 23 (2.9) 0.77
Leading to discontinuation 3 (0.4) 5 (0.6) 7 (0.5) 5 (0.4) 9 (0.7) 12 (0.9) 10 (1.3) 14 (1.8) 0.94
Renal impairment, N (%)
Serum creatinine ≥2.5 mg/dL 20 (2.6) 10 (1.2) 48 (3.5) 34 (2.7) 74 (5.9) 62 (4.8) 46 (5.9) 33 (4.2) 0.49
Serum creatinine ≥3.0 mg/dL 12 (1.5) 5 (0.6) 27 (2.0) 18 (1.4) 28 (2.2) 26 (2.0) 16 (2.1) 14 (1.8) 0.28
Leading to discontinuation 9 (1.1) 9 (1.1) 14 (1.0) 4 (0.3) 20 (1.6) 11 (0.9) 16 (2.1) 5 (0.6) 0.10
Hyperkalaemia, N (%)
Serum potassium .5.5 mmol/L 89 (11.4) 97 (11.7) 254 (18.5) 220 (17.4) 232 (18.4) 218 (16.9) 152 (19.5) 139 (17.7) 0.70
Serum potassium .6.0 mmol/L 23 (2.9) 28 (3.4) 82 (6.0) 57 (4.5) 75 (6.0) 58 (4.5) 56 (7.2) 38 (4.8) 0.17
Leading to discontinuation 0 (0) 3 (0.4) 3 (0.2) 1 (0.1) 8 (0.6) 3 (0.2) 4 (0.4) 4 (0.5) 0.97
Cough, N (%)
Any cough 137 (17.4) 106 (12.6) 198 (14.3) 130 (10.2) 167 (13.2) 161 (12.5) 99 (12.7) 77 (9.8) 0.58
Leading to discontinuation 4 (0.5) 0 (0) 14 (1.0) 4 (0.3) 7 (0.6) 3 (0.2) 5 (0.6) 1 (0.1) 0.73
Angioedema (adjudicated)
No treatment/antihistamines only 2 (0.3%) 1 (0.1%) 1 (0.1%) 3 (0.2%) 1 (0.1%) 5 (0.4%) 1 (0.1%) 1 (0.1%) 0.20
Catecholamines/corticosteroids
without hospitalization
1 (0.1%) 2 (0.2%) 2 (0.1%) 3 (0.2%) 0 (0.0%) 1 (0.1%) 1 (0.1%) 0 (0.0%) 0.58
Hospitalized/no airway compromise 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (0.2%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.52
Airway compromise 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) –
Any adverse event leading to study-drug
discontinuation, N (%)
16 (2.0%) 14 (1.7%) 35 (2.5%) 14 (1.1%) 43 (3.4%) 29 (2.2%) 35 (4.5%) 22 (2.8%) 0.85
+P-value for interaction.
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The median KCCQ clinical summary score was only notably low-
er in the oldest age group (compared with the younger age categor-
ies), showing that differences in health-related quality of life, like
those for hospitalization and mortality, did not become marked until
the age of 75 years or older.
From a treatment perspective, the most important finding was
that the benefit of LCZ696 over enalapril was consistent across
the age categories studied, although in the analysis of age as a con-
tinuous variable there was some uncertainty about fatal outcomes in
the most elderly patients because of the modest number of patients
age 85 years or older (n ¼ 121). However, even in very elderly pa-
tients the effect of LCZ696 on heart failure hospitalization seemed
qualitatively and quantitatively similar to its effect in younger pa-
tients. This finding is consistent with many but not all12 prior ana-
lyses of treatment effect by age, although some of these have
been truncated by an upper inclusion age-limit or the enrolment
few elderly patients in the trials concerned.12–14,22– 24
The effect of treatment on the KCCQ according to age has not
been reported previously and in PARADIGM-HF, as with other out-
comes, LCZ696 was superior to enalapril across the age-range
examined in preventing deterioration in this measure of health-
related quality of life, even in the most elderly group.
As anticipated from prior studies, treatment intolerance in-
creased with increasing age (with the exception of angioedema), al-
though the gradient was modest and the difference between
LCZ696 and enalapril persisted across age categories. Overall, it is
clear that the benefit–risk profile of LCZ696 compared with enala-
pril remained favourable across the broad spectrum of age studied.
Despite this consistent finding with multiple drug treatments in
heart failure, there is ample evidence that older patients with heart
failure are often under-treated with therapies that reduce mortality
and morbidity.25– 30
As with any study, this one has some limitations. This is a retro-
spective analysis and the age-categories are arbitrary (although
commonly used and clinically meaningful). We enrolled a relatively
small number of the most elderly patients. The number of African-
American patients was also relatively small. The safety and adverse
event data must be interpreted in the light of the trial design with an
enalapril and LCZ696 active run-in period.
In summary, our analyses showed that LCZ696 was more bene-
ficial than enalapril across the broad spectrum of age studied in
PARADIGM-HF and that intolerance of LCZ696 leading to treat-
ment withdrawal was uncommon, even in elderly individuals.
Supplementary material
Supplementary material is available at European Heart Journal online.
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